GSK plc

GSKUnited KingdomAlso United States · GSK

28 filed reports · 1,159 financial concepts · 43 earnings calls · 5 media appearances

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

£32.7B

FY2025 · to Dec 31, 2025

up +4.1% vs £31.4B

20-F

Net income

£6.29B

FY2025 · to Dec 31, 2025

up +113% vs £2.95B

20-F

Operating income

£7.93B

FY2025 · to Dec 31, 2025

up +97.3% vs £4.02B

20-F

Latest quarter

Revenue

£8.89B

Q3 FY2026 · to Sep 30, 2026

up +4.0% vs £8.55B

6-K

Net income

—

Operating income

£481M

Q2 FY2026 · to Jun 30, 2026

down −76.2% vs £2.02B

6-K

Filed reports

28 reports · Dec 2017 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 9 guidance figures.

Report typeReportsFactsPeriods
Annual · ACSFCA National Storage Mechanism51,082Dec 2021 to Dec 2025
Half YearFCA National Storage Mechanism3436Jun 2024 to Jun 2026
Q1FCA National Storage Mechanism2230Mar 2025 to Mar 2026
Q3FCA National Storage Mechanism2274Sep 2025 to Sep 2026
Annual · 20-FSEC EDGAR86,679Dec 2018 to Dec 2025
Interim · 6-KSEC EDGAR7129Jun 2025 to Sep 2026
Annual · 20-F/ASEC EDGAR1725Dec 2017

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q36-K2026-09-302026-10-2876Open
FY2026 Q3q32026-09-302026-10-28158Open
FY2026 Q26-K2026-06-302026-09-0810Open
FY2026 Q26-K2026-06-302026-07-289Open
FY2026 Q2half year2026-06-302026-07-28152Open
FY2026 Q16-K2026-03-312026-04-2910Open
FY2026 Q1q12026-03-312026-04-2999Open
FY202520-F2025-12-312026-03-061,493Open
FY2025ACS2025-12-312026-03-05277Open
FY2025 Q46-K2025-12-312026-02-0410Open
FY2025 Q3q32025-09-302025-10-29116Open
FY2025 Q36-K2025-09-302025-10-299Open

Financial data

1,159 concepts · 9,555 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial841 concepts · 6,768 facts · Dec 2015 to Sep 2026

  • Retained earnings37 · Dec 2015 to Dec 2025
  • Net debt29 · Dec 2016 to Dec 2025
  • Shionogi ViiV healthcare29 · Dec 2015 to Dec 2025
  • Financial liabilities26 · Dec 2016 to Dec 2025
  • Equity23 · Dec 2015 to Dec 2025
  • Other reserves (IFRS)23 · Dec 2015 to Dec 2025
  • Revenue23 · Dec 2015 to Sep 2026
  • Bank overdrafts classified as cash equivalents22 · Dec 2015 to Dec 2025
  • Borrowings22 · Dec 2015 to Dec 2025
  • Cash and cash equivalents22 · Dec 2015 to Dec 2025
  • Cash and cash equivalents if different from statement of financial position22 · Dec 2015 to Dec 2025
  • Contingent liabilities recognised in business combination22 · Dec 2015 to Dec 2025
  • Deferred tax assets22 · Dec 2016 to Sep 2026
  • Defined benefit obligation at present value22 · Dec 2015 to Dec 2025
  • Goodwill (IFRS)22 · Dec 2015 to Dec 2025
  • Intangible assets, for which impairments have been charged or reversed22 · Dec 2016 to Dec 2025
  • Intangible assets other than goodwill22 · Dec 2015 to Dec 2025
  • Investments in subsidiaries joint ventures and associates22 · Dec 2015 to Dec 2025
  • Liability asset of defined benefit plans22 · Dec 2015 to Dec 2025
  • Noncontrolling interests22 · Dec 2016 to Sep 2026
  • Noncurrent provisions for employee benefits (IFRS)22 · Dec 2015 to Dec 2025
  • Number of shares issued and fully paid22 · Dec 2015 to Dec 2025
  • Property plant and equipment22 · Dec 2015 to Dec 2025
  • Reserve of exchange differences on translation22 · Dec 2015 to Dec 2025

IFRS234 concepts · 1,844 facts · Dec 2020 to Sep 2026

  • Total Comprehensive Income50 · Dec 2020 to Sep 2026
  • Stockholders Equity42 · Dec 2020 to Dec 2025
  • Other Comprehensive Income40 · Dec 2020 to Dec 2025
  • Dividends Paid39 · Dec 2020 to Dec 2025
  • Issue of Equity39 · Dec 2020 to Dec 2025
  • Net Income39 · Dec 2020 to Dec 2025
  • Equity Change: Share-Based Payment Transactions38 · Dec 2020 to Dec 2025
  • Equity Change: Tax on Share-Based Payments38 · Dec 2020 to Dec 2025
  • Dividends Recognised as Distributions to Noncontrolling Interests37 · Dec 2020 to Dec 2025
  • Equity Change: Transfers and Other Changes21 · Dec 2020 to Dec 2022
  • Derivative financial instruments18 · Jun 2024 to Sep 2026
  • Finance Income18 · Dec 2020 to Sep 2026
  • Gross Profit18 · Dec 2020 to Sep 2026
  • Other Operating Income (Expense)18 · Dec 2020 to Sep 2026
  • Fair value movements on cash flow hedges16 · Jun 2024 to Sep 2026
  • Other Reserves16 · Dec 2020 to Sep 2026
  • Retained Earnings (Accumulated Deficit)16 · Dec 2020 to Sep 2026
  • Share Premium16 · Dec 2020 to Sep 2026
  • Issued Share Capital15 · Dec 2020 to Sep 2026
  • Cash Flow Hedge Reserve Transferred to Non-Financial Assets or Liabilities14 · Dec 2023 to Dec 2024
  • Equity Change: Disposal of Subsidiary14 · Dec 2022 to Dec 2024
  • Income Tax Expense (Benefit)14 · Dec 2020 to Sep 2026
  • Deferred tax assets13 · Dec 2020 to Sep 2026
  • Goodwill13 · Dec 2020 to Sep 2026

Segment30 concepts · 602 facts · Dec 2015 to Sep 2026

  • Revenue199 · Dec 2015 to Dec 2023
  • Revenue from sale of goods (IFRS)75 · Dec 2022 to Dec 2025
  • Average number of employees30 · Dec 2015 to Dec 2025
  • Depreciation and amortisation expense30 · Dec 2015 to Dec 2020
  • Profit loss from operating activities30 · Dec 2015 to Dec 2020
  • Impairment loss recognised in profit or loss29 · Dec 2015 to Dec 2020
  • Goodwill26 · Dec 2016 to Dec 2025
  • Reversal of impairment loss recognised in profit or loss25 · Dec 2015 to Dec 2020
  • Manufacturing21 · Dec 2020 to Dec 2024
  • Six months ended 30 June 202419 · Jun 2024 to Sep 2026
  • Three months ended 30 June 202412 · Jun 2024 to Sep 2026
  • Three months ended 30 June 202512 · Jun 2025 to Jun 2026
  • Other General Medicines11 · Mar 2025 to Jun 2026
  • General Medicines9 · Mar 2025 to Jun 2026
  • Seretide/Advair9 · Mar 2025 to Jun 2026
  • Other Respiratory8 · Mar 2025 to Jun 2026
  • Trelegy Ellipta7 · Mar 2025 to Jun 2026
  • Ventolin7 · Mar 2025 to Jun 2026
  • Respiratory6 · Mar 2025 to Sep 2025
  • Depreciation & Amortization5 · Dec 2016 to Dec 2020
  • Operating Income5 · Dec 2016 to Dec 2020
  • US [member]5 · Dec 2017 to Dec 2021
  • Commercial Operations4 · Jun 2026 to Sep 2026
  • Flixotide/Flovent4 · Mar 2025 to Jun 2025

Geography24 concepts · 251 facts · Dec 2015 to Dec 2025

  • UK36 · Dec 2017 to Dec 2025
  • Return on plan assets net defined benefit liability asset35 · Dec 2015 to Dec 2025
  • Current tax expense income22 · Dec 2015 to Dec 2025
  • US18 · Dec 2015 to Dec 2023
  • Contributions to plan by employer net defined benefit liability asset16 · Dec 2015 to Dec 2022
  • Current service cost net defined benefit liability asset12 · Dec 2015 to Dec 2018
  • Gain loss on remeasurement of net defined benefit liability asset12 · Dec 2015 to Dec 2018
  • Interest expense income net defined benefit liability asset12 · Dec 2015 to Dec 2018
  • Payments from plan net defined benefit liability asset12 · Dec 2015 to Dec 2018
  • Revenue from sale of goods (IFRS)12 · Dec 2023 to Dec 2025
  • Past service cost net defined benefit liability asset10 · Dec 2015 to Dec 2018
  • Contributions to plan by plan participants net defined benefit liability asset9 · Dec 2015 to Dec 2018
  • Increase decrease through changes in foreign exchange rates net defined benefit liability asset9 · Dec 2015 to Dec 2018
  • Applicable tax rate8 · Dec 2019 to Dec 2025
  • Gains losses arising from settlements net defined benefit liability asset7 · Dec 2015 to Dec 2018
  • Income taxes paid refund5 · Dec 2021 to Dec 2025
  • Tax expense income at applicable tax rate5 · Dec 2021 to Dec 2025
  • UK [member]4 · Dec 2017 to Dec 2020
  • US [member]2 · Dec 2018 to Dec 2022
  • Deferred tax relating to items charged or credited directly to equity1 · Dec 2017
  • Increase decrease through business combinations and disposals net defined benefit liability asset1 · Dec 2015
  • Other tax effects for reconciliation between accounting profit and tax expense income1 · Dec 2017
  • Proceeds from disposal of noncurrent assets or disposal groups classified as held for sale and discontinued operations1 · Dec 2018
  • US and Belgium [member]1 · Dec 2017

APM15 concepts · 48 facts · Jun 2024 to Sep 2026

  • Adjusting items9 · Jun 2024 to Sep 2026
  • Free cash inflow5 · Mar 2025 to Sep 2026
  • Contingent consideration on acquisition of Affinivax3 · Jun 2024 to Sep 2026
  • Contingent consideration on former Novartis Vaccines business3 · Jun 2024 to Sep 2026
  • Contingent consideration on former Shionogi-ViiV Healthcare joint Venture (including Shionogi preferential dividends)3 · Jun 2024 to Sep 2026
  • Legacy programmes3 · Sep 2026
  • Major restructuring programmes3 · Sep 2026
  • net debt3 · Jun 2024 to Sep 2025
  • Other adjustments3 · Jun 2024 to Sep 2026
  • Total transaction-related charges3 · Jun 2024 to Sep 2026
  • ViiV Healthcare put options and Pfizer preferential dividends3 · Jun 2024 to Sep 2026
  • Core operating profit2 · Mar 2025 to Jun 2026
  • Other contingent consideration2 · Sep 2025 to Sep 2026
  • Significant acquisitions2 · Sep 2026
  • Net debt increased1 · Mar 2025

Guidance9 concepts · 18 facts · Jul 2026 to Oct 2026

  • Effective Tax Rate Guidance4 · Jul 2026 to Oct 2026
  • EPS (Diluted) Growth Guidance2 · Jul 2026
  • EPS (Diluted) Growth Guidance (Adjusted, constant currency)2 · Oct 2026
  • Operating Income Growth Guidance2 · Jul 2026
  • Operating Income Growth Guidance (Adjusted, constant currency)2 · Oct 2026
  • Revenue Growth Guidance2 · Jul 2026
  • Revenue Growth Guidance (Constant currency)2 · Oct 2026
  • Revenue Guidance1 · Jul 2026
  • Revenue Guidance (Constant currency)1 · Oct 2026

Product4 concepts · 15 facts · Dec 2017 to Dec 2024

  • Revenue9 · Dec 2019 to Dec 2023
  • Revenue from sale of goods (IFRS)3 · Dec 2022 to Dec 2024
  • Oncology product [member]2 · Dec 2017
  • Decrease through classified as held for sale goodwill1 · Dec 2022

KPI2 concepts · 9 facts · Jun 2024 to Sep 2026

  • Tax rate %8 · Jun 2024 to Sep 2026
  • shares1 · Sep 2026

Segments

1,209 facts

Figures broken down by business line, region, product or another axis the company reports on.

Segments16 members · 481 facts

  • Commercial Operations144 · Dec 2020 to Dec 2025
  • Consumer Healthcare76 · Dec 2015 to Dec 2022
  • Pharmaceuticals63 · Dec 2015 to Dec 2021
  • Vaccines59 · Dec 2015 to Dec 2021
  • Pharmaceuticals Including Research And Development24 · Dec 2015 to Dec 2020
  • Pharmaceuticals Research And Development23 · Dec 2015 to Dec 2020
  • Manufacturing17 · Dec 2015 to Dec 2025
  • Research And Development17 · Dec 2015 to Dec 2025
  • Selling General And Administration17 · Dec 2015 to Dec 2025
  • Pharmaceuticals including research and development10 · Dec 2016 to Dec 2020
  • Consumer healthcare6 · Dec 2016 to Dec 2021
  • Pharmaceuticals6 · Dec 2016 to Dec 2021
  • Vaccines6 · Dec 2016 to Dec 2021
  • Pharmaceuticals And Vaccines5 · Dec 2017 to Dec 2021
  • Commercial operations4 · Dec 2022 to Dec 2025
  • Research and development4 · Dec 2022 to Dec 2025

Components of equity6 members · 341 facts

  • Equity attributable to owners of parent61 · Dec 2020 to Dec 2025
  • Retained earnings60 · Dec 2020 to Dec 2025
  • Noncontrolling interests57 · Dec 2020 to Dec 2025
  • Other reserves55 · Dec 2020 to Dec 2025
  • Issued capital54 · Dec 2020 to Dec 2025
  • Share premium54 · Dec 2020 to Dec 2025

Geographical areas9 members · 250 facts

  • GB92 · Dec 2015 to Dec 2025
  • US77 · Dec 2015 to Dec 2025
  • Rest Of World52 · Dec 2015 to Dec 2025
  • Foreign Countries11 · Dec 2015 to Dec 2025
  • Country Of Domicile8 · Dec 2022 to Dec 2025
  • Europe3 · Dec 2023 to Dec 2025
  • International3 · Dec 2023 to Dec 2025
  • US And Belgium3 · Dec 2017
  • BE1 · Dec 2019

Commercial operations geography4 members · 56 facts

  • Europe18 · Mar 2025 to Jun 2026
  • International18 · Mar 2025 to Jun 2026
  • US16 · Mar 2025 to Jun 2026
  • Commercial Operations4 · Jun 2024

General medicinesbusiness: General Medicines4 members · 24 facts

  • Total7 · Jun 2026
  • Europe6 · Jun 2026
  • International6 · Jun 2026
  • US5 · Jun 2026

Products and services5 members · 15 facts

  • HIV Oncology Immuno Inflammation Respiratory And Other6 · Dec 2021 to Dec 2024
  • New And Speciality3 · Dec 2019 to Dec 2021
  • Sub Total3 · Dec 2020 to Dec 2022
  • Oncology Business2 · Dec 2017
  • Consumer Healthcare1 · Dec 2022

Business1 member · 13 facts

  • Commercial Operations13 · Jun 2024 to Sep 2026

Commercial operationsCommercial Operations4 members · 9 facts

  • Total3 · Mar 2025 to Sep 2025
  • Europe2 · Sep 2025
  • International2 · Sep 2025
  • US2 · Sep 2025

General medicinesGeneral Medicines4 members · 7 facts

  • US3 · Sep 2025
  • Europe2 · Sep 2025
  • International1 · Sep 2025
  • Total1 · Mar 2025

Commercial operationsbusiness: Commercial Operations1 member · 6 facts

  • Commercial Operations6 · Jun 2026 to Sep 2026

General medicines product1 member · 4 facts

  • Total4 · Jun 2025

Geography2 members · 2 facts

  • International1 · Jun 2025
  • US1 · Jun 2026

Statement geographical1 member · 1 fact

  • IN1 · Dec 2018

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Management discussion (MD&A) commentary52 claims from 2 reports · Dec 2024 to Dec 2025
  • Risk-factor changes48 claims from 4 reports · Dec 2019 to Dec 2022
  • Risk factors108 risks from 6 annual reports · 2018 to 2025

Earnings calls

43 calls · Apr 2016 to Oct 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-10-28
  • FY2026 Q22026-07-28
  • FY2026 Q12026-04-29
  • FY2025 Q42026-02-04
  • FY2025 Q32025-10-29
  • FY2025 Q22025-07-30
  • FY2025 Q12025-04-30
  • FY2024 Q42025-02-05
  • FY2024 Q32024-10-30
  • FY2024 Q22024-07-31
  • FY2024 Q12024-05-01
  • FY2023 Q42024-01-31
  • FY2023 Q32023-11-01
  • FY2023 Q22023-07-26
  • FY2023 Q12023-04-26
  • FY2022 Q42023-02-01

Executive media

5 appearances

Podcasts, interviews and conference appearances by the company's executives, with their claims.

  • Other appearances2 · Nov 2020 to Jun 2022
  • Podcasts2 · Oct 2023 to Apr 2025
  • TV interviews1 · Jul 2025

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of GSK plc (GSK) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 21, 2026) and refreshed every few hours.

GSK plc (GSK): FY2025 revenue £32.7B · FactIQ